StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Zirabev [legacy through FY23] by Quarter

Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Zirabev [legacy through FY23]: $66M in Q4 2023, down 32.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
66
Period ended Dec 31, 2023
Change on a year earlier
-32.0%
97 in Q4 2022
History
17 quarters
Since Q4 2019
Sources
13
Documents cited below

Where the Q4 2023 figure comes from

“|| Zirabev | 88 | 130 | (32%) | (32%) | 66 | 97 | (31%) | 22 | 33 | (34%) | (32%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202366-32.0%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202366-41.1%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202374-24.5%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202398-7.5%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 202297+12.8%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 2022112+100.0%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 202298+36.1%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 2022106+231.3%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2021Dec 31, 202186+168.8%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2021Oct 3, 202156+154.5%Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2021Jul 4, 202172+1,100.0%Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2021Apr 4, 202132+700.0%Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2020Dec 31, 202032+3,100.0%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2020Sep 27, 202022–Form 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗
Q2 2020Jun 28, 20206–Form 8-K (Earnings / Guidance Release) (pfe-07042021xex99.htm, filed 2021-07-28) ↗
Q1 2020Mar 29, 20204–Form 8-K (Earnings / Guidance Release) (pfe-04042021xex99.htm, filed 2021-05-04) ↗

Breakdown

What makes up zirabev [legacy through FY23]

Cite this data

StockData. (2026). Pfizer Zirabev [legacy through FY23] ($M), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.